Back to Search
Start Over
Metabolic-Associated Fatty Liver Disease and the Gut Microbiota
- Source :
- Endocrinology and Metabolism Clinics of North America; September 2023, Vol. 52 Issue: 3 p485-496, 12p
- Publication Year :
- 2023
-
Abstract
- As an important sequela of the burgeoning global obesity problem, metabolic-associated fatty liver disease (MAFLD) has gained increasing prominence recently. The gut–liver axis (GLA) provides a direct conduit to the liver for the gut microbiota and their metabolic by-products (including secondary bile acids, ethanol, and trimethylamine). These GLA-related factors, including the host inflammatory response and integrity of the gut mucosal wall, likely contribute to the pathogenesis of MAFLD. Accordingly, these GLA-related factors are targets for possible preventive and treatment strategies for MAFLD, and include probiotics, prebiotics, bile acids, short-chain fatty acids, fecal microbiota transplantation, carbon nanoparticles, and bacteriophages.
Details
- Language :
- English
- ISSN :
- 08898529
- Volume :
- 52
- Issue :
- 3
- Database :
- Supplemental Index
- Journal :
- Endocrinology and Metabolism Clinics of North America
- Publication Type :
- Periodical
- Accession number :
- ejs61808685
- Full Text :
- https://doi.org/10.1016/j.ecl.2023.01.004